Inactive Instrument

Cipher Pharmaceuticals Inc Share Price Nasdaq

Equities

CA17253X1050

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 3.01Cr 2.21Cr 184.36Cr Sales 2025 * 2.94Cr 2.16Cr 179.81Cr Capitalization 21Cr 15Cr 1.28TCr
Net income 2024 * 1.8Cr 1.32Cr 110.08Cr Net income 2025 * 1.6Cr 1.17Cr 98Cr EV / Sales 2024 * 6.95 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 7.13 x
P/E ratio 2024 *
11.7 x
P/E ratio 2025 *
13.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.49%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 26/19/26
Director of Finance/CFO - 15/22/15
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 72 08/16/08
Director/Board Member 76 21/23/21
Chief Executive Officer - 26/19/26
More insiders
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW